SAN FRANCISCO, Aug. 15, 2017 /PRNewswire/ -- Ava, a medical technology company focused on innovations in women's reproductive health, today announced the birth of the first baby conceived with the help of its Ava fertility tracking sensor bracelet launched to consumers last summer.
Ava user Lizzie McGee, 32, and her husband, Sam, 31, welcomed son Jace McGee, a healthy 6 lb., 10oz. boy, on July 11, 2017 becoming the first confirmed "Ava baby" born since the bracelet's official consumer debut.
Lizzie, a hairstylist in St. George, Utah, found out about Ava after struggling for over a year to get pregnant with her second child: "The experience of conceiving our first child was really difficult and stressful on our marriage, and I didn't want to go through the same thing again with our second," said McGee, who conceived Jace after wearing Ava for three months.
According to Ava Co-founder Lea von Bidder, McGee is one of over one-third of Ava users who purchased the bracelet to aid in conceiving a second child. "Secondary infertility is much more common than many people realize," von Bidder explained, "especially in cases where a couple has started their family later in life because it's widely known that fertility decreases as maternal age increases. Ava helps women optimize their chances of conception at any age by identifying in real time her full fertile window, not just the day of ovulation."
Since its consumer launch in August 2016, the Ava fertility tracking bracelet has already helped over 500 women conceive. According to von Bidder, Ava users from across the US and Europe are reporting about 5-10 pregnancies a day.
How Ava Works
Ava is a sensor bracelet that uses new technology to precisely detect the fertile days during a woman's monthly cycle in real time. Worn only at night while sleeping, Ava measures nine physiological parameters including pulse rate, breathing rate, heart rate variability, temperature that, in combination, help indicate a rise in reproductive hormones estradiol and progesterone. The impact of the rise of these hormones on the physiological parameters is used to detect a 5.3-day fertile window in a woman's cycle. Because users simply wear the Ava bracelet at night and sync it with the Ava app in the morning, they avoid the hassles, mess and invasiveness of other fertility tracking methods like ovulation strips and BBT thermometers. An FDA Class 1 medical device, the Ava bracelet was proven in a recently concluded clinical study at the University Hospital of Zurich to detect an average of 5.3 fertile days per cycle - in real time - with 89 percent accuracy.
Founded in Switzerland in 2014 by Pascal Koenig, Philipp Tholen, Peter Stein and Lea von Bidder, Ava is a medical technology company dedicated to bringing innovation to women's reproductive health. The Ava bracelet, which received The Bump "Best of Baby Tech CES 2017" award for fertility and pregnancy, is the company's first consumer product. It uses sensor technology combined with clinically tested data science to precisely detect a woman's entire fertile window in real time. The company is also conducting clinical studies to adapt and expand its algorithms for use in pregnancy monitoring, and future use as a non-hormonal contraceptive device. Backed by $12.3M in seed and Series A funding, Ava has operations in Zurich and San Francisco.